GARDP at one: R&D programmes getting underway

GARDP at one year old

GARDP has set up its team, scientific advisory committee, and R&D strategy. Three programmes are underway: neonatal sepsis, gonorrhoea, and an initiative to recover and connect the vital knowledge of scientists in antibiotic drug development. In recent weeks, both the G20 Health Ministers and outgoing WHO Director-General Margaret Chan have expressed support for GARDP and called for more R&D into drug-resistant infections.

NTD Summit 2017: this is not (yet) the endgame

Bernard Pécoul, Executive Director, DNDi
[May 2017]

Ambitious targets serve the obvious purpose of galvanising the NTD community around a shared goal, and the London Declaration succeeded in bringing new actors to the table and casting a much-needed spotlight on the neglect of these diseases. But the job is far from done, and we should not be lulled into a sense of security or complacency by too much celebrating of good news.

The search for treatments for HIV/VL co-infected patients continues

HIV-VL patient with nurseVisceral Leishmaniasis
Ethiopia

Thirty-five year old Tsadik is a visceral leishmaniasis (VL) patient who is also infected with HIV. He is gaunt, weak and tired, with sunken eyes. Each breath he takes is laboured. Tsadik lives in Abdurafi, a region of northwest Ethiopia that is characterized with high VL-HIV co-infection because VL is endemic….

Caring for Kids with HIV and TB

Sani sits in the doorway of her one-room house with her baby girl Mel in her arms. A pink sunset illuminates the Durban township of KwaMashu that unfolds below her clifftop house. She looks lovingly at Mel, then takes out a syringe and struggles to give the two-year-old,a medicine that is over 40% alcohol.

Renewed commitment of the German Government to neglected diseases

KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi

DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.